Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life

INTRODUCTION: Given the relatively short life expectancy of patients with hepatocellular carcinoma (HCC), quality of life (QOL) plays a significant role in treatment selection. This analysis aimed to compare time to deterioration (TTD) in QOL with transarterial radioembolization (TARE) and atezolizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Agirrezabal, Ion, Brennan, Victoria K., Colaone, Fabien, Shergill, Suki, Pereira, Helena, Chatellier, Gilles, Vilgrain, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056454/
https://www.ncbi.nlm.nih.gov/pubmed/35279814
http://dx.doi.org/10.1007/s12325-022-02099-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056454/
https://www.ncbi.nlm.nih.gov/pubmed/35279814
http://dx.doi.org/10.1007/s12325-022-02099-0

Ejemplares similares